Rosuvastatin

[1]  A. Olsson,et al.  Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. , 2006, Cardiovascular drug reviews.

[2]  P. Ridker.  Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. , 2003, Circulation.

[3]  S. Palmer,et al.  THE COST‐EFFECTIVENESS OF A NEW STATIN (ROSUVASTATIN) IN THE UK NHS , 2003, International journal of clinical practice.

[4]  H. Schuster,et al.  PCV46 SWITCHING PATIENTS TO ROSUVASTATIN FROM ATORVASTATIN OR OTHER STATINS IS COST-EFFECTIVE: PHARMACOECONOMIC ANALYSIS OF MERCURY I , 2003 .

[5]  Paul D. Martin,et al.  Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. , 2003, Clinical therapeutics.

[6]  E. Frohlich,et al.  Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. , 2003, Journal of the American College of Cardiology.

[7]  Robert Kleemann,et al.  Rosuvastatin Reduces Atherosclerosis Development Beyond and Independent of Its Plasma Cholesterol–Lowering Effect in APOE*3-Leiden Transgenic Mice: Evidence for Antiinflammatory Effects of Rosuvastatin , 2003, Circulation.

[8]  M. Nangle,et al.  Effects of rosuvastatin on nitric oxide-dependent function in aorta and corpus cavernosum of diabetic mice: relationship to cholesterol biosynthesis pathway inhibition and lipid lowering. , 2003, Diabetes.

[9]  H. Brewer,et al.  Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. , 2003, The American journal of cardiology.

[10]  Elinor Miller,et al.  Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). , 2003, The American journal of cardiology.

[11]  M. Clearfield.  Evolution of Cholesterol Management Therapies: Exploiting Potential for Further Improvement , 2003, American journal of therapeutics.

[12]  D. Capuzzi,et al.  Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. , 2003, The American journal of cardiology.

[13]  H. Schuster.  Rosuvastatin – A Highly Effective New 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor: Review of Clinical Trial Data at 10–40 mg Doses in Dyslipidemic Patients , 2003, Cardiology.

[14]  H. Bays,et al.  Colesevelam HCl: a non-systemic lipidaltering drug , 2003, Expert opinion on pharmacotherapy.

[15]  M. Bottorff,et al.  Treating Dyslipidemic Patients with Lipid‐Modifying and Combination Therapies , 2003, Pharmacotherapy.

[16]  A. M. Lefer,et al.  Rosuvastatin, a New HMG-CoA Reductase Inhibitor, Protects Ischemic Reperfused Myocardium in Normocholesterolemic Rats , 2003, Journal of cardiovascular pharmacology.

[17]  J. Mckenney,et al.  Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003. , 2003, Atherosclerosis. Supplements.

[18]  E. Stein,et al.  Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. , 2003, The American journal of cardiology.

[19]  C. Ballantyne,et al.  Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. , 2003, The American journal of cardiology.

[20]  D. Rader,et al.  Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. , 2003, The American journal of cardiology.

[21]  L. Clark.  Treating dyslipidemia with statins: the risk-benefit profile. , 2003, American heart journal.

[22]  F. McTaggart.  Comparative pharmacology of rosuvastatin. , 2003, Atherosclerosis. Supplements.

[23]  P. Jones.  P2362 Statin therapies for elevated lipid levels compared across doses to rosuvastatin (STELLAR): non-high-density lipoprotein cholesterol results and goals , 2003 .

[24]  C. Napoli,et al.  Statin effects beyond lipid lowering--are they clinically relevant? , 2003, European heart journal.

[25]  Paul D. Martin,et al.  An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. , 2003, Clinical therapeutics.

[26]  J. Mckenney,et al.  Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial , 2003, Current medical research and opinion.

[27]  A. Gotto.  Treating hypercholesterolemia: Looking forward , 2003, Clinical cardiology.

[28]  P. Chong.  Therapeutic Controversies; Lack of Therapeutic Interchangeability of HMG-CoA Reductase Inhibitors , 2002 .

[29]  J. Tuomilehto,et al.  Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. , 2002, American heart journal.

[30]  J. Mckenney,et al.  Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. , 2002, American heart journal.

[31]  E. Stein.  Management of dyslipidemia in the high-risk patient. , 2002, American heart journal.

[32]  Paul D. Martin,et al.  No Effect of Rosuvastatin on the Pharmacokinetics of Digoxin in Healthy Volunteers , 2002, Journal of clinical pharmacology.

[33]  H. Hasegawa,et al.  Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[34]  Paul D. Martin,et al.  Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. , 2002, British journal of clinical pharmacology.

[35]  R. Subramanian,et al.  Effects of fibrates on metabolism of statins in human hepatocytes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[36]  A. Dane,et al.  The effect of fluconazole on the pharmacokinetics of rosuvastatin , 2002, European Journal of Clinical Pharmacology.

[37]  M. Endres,et al.  Bone Marrow–Derived Progenitor Cells Modulate Vascular Reendothelialization and Neointimal Formation: Effect of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[38]  Steven P Jones,et al.  Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. , 2002, Journal of the American College of Cardiology.

[39]  J. Mckenney.  New Cholesterol Guidelines, New Treatment Challenges , 2002, Pharmacotherapy.

[40]  M. Chapman,et al.  Optimizing the pharmacology of statins: characteristics of rosuvastatin. , 2002, Atherosclerosis. Supplements.

[41]  A. Gotto,et al.  Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. , 2002, The American journal of cardiology.

[42]  A. Olsson,et al.  Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. , 2001, The American journal of cardiology.

[43]  J. Larosa,et al.  Pleiotropic effects of statins and their clinical significance. , 2001, American Journal of Cardiology.

[44]  A. M. Lefer,et al.  A new HMG‐CoA reductase inhibitor, rosuvastatin, exerts anti‐inflammatory effects on the microvascular endothelium: the role of mevalonic acid , 2001, British journal of pharmacology.

[45]  K. Bleasby,et al.  Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C , 2001 .

[46]  R. Davidson,et al.  Kinetics of inhibition of HMG-CoA reductase by a new statin, rosuvastatin , 2001 .

[47]  R. Davidson,et al.  Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. , 2001, The American journal of cardiology.

[48]  R. Davidson,et al.  Pharmacological properties of ZD4522 — A new HMG-CoA reductase inhibitor , 2000 .

[49]  R. Davidson,et al.  Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells , 2000 .

[50]  K. Goa,et al.  Management of Dyslipidaemias , 2000 .

[51]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[52]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[53]  K. Hirai,et al.  Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. , 1997, Bioorganic & medicinal chemistry.

[54]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[55]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[56]  J. Mckenney,et al.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.

[57]  J. Balligand,et al.  4P-1061 Altered blood pressure and heart rate variability in hypercholesterolemic apoE-/-mice is corrected by rosuvastatin independently of its plasma lipid lowering activity , 2003 .

[58]  H. Schuster,et al.  2P-0594 Rosuvastatin is cost-effective compared with other statins: Pharmacoeconomic analysis of MERCURY I , 2003 .

[59]  E. Tremoli,et al.  4P-1081 Rosuvastatin displays anti-atherothrombotic properties in apo E-deficient mice , 2003 .

[60]  C. Watkins,et al.  1P-0281 Switching to rosuvastatin from other statins has beneficial effects on lipid ratios , 2003 .

[61]  A. Cheng-Lai.  Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. , 2003, Heart disease.

[62]  M. D. de Broe,et al.  Crystal retention capacity of cells in the human nephron: involvement of CD44 and its ligands hyaluronic acid and osteopontin in the transition of a crystal binding- into a nonadherent epithelium. , 2003, Journal of the American Society of Nephrology : JASN.

[63]  R. McPherson,et al.  Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. , 2003, The American journal of cardiology.

[64]  P. Deedwania,et al.  2P-0586 Rosuvastatin compared with atorvastatin, simvastatin, and pravastatin for lipid ratios (STELLAR trial results) , 2003 .

[65]  J. Larosa.  Reduction of Serum LDL-C Levels , 2003 .

[66]  M. Hirsch,et al.  2P-0595 Cost-effectiveness of rosuvastatin: A pharmacoeconomic analysis of statin dose comparisons in the STELLAR trial , 2003 .

[67]  Paul D. Martin,et al.  Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. , 2003, British journal of clinical pharmacology.

[68]  C. Packard,et al.  3P-0786 Rosuvastatin: Kinetics of apoB-containing lipoproteins in moderate hypercholesterolemia , 2003 .

[69]  S. Oparil,et al.  4P-1039 Rosuvastatin-induced modulation of NO-dependent superoxide formation , 2003 .

[70]  Marc Evans,et al.  Effects of HMG-CoA Reductase Inhibitors on Skeletal Muscle , 2002, Drug safety.